Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

TARRYTOWN, N.Y., April 07, 2024 -- Regeneron Pharmaceuticals, Inc. today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial of...

Related Keywords

United States ,San Diego ,California ,Tarrytown ,New York ,American ,Sundar Jagannath ,Tammy Allen ,Vesna Tosic ,Linkedin ,Tisch Cancer Center ,Nasdaq ,Myeloma Center ,Globenewswire Inc ,European Medicines Agency ,Regeneron Genetics Center ,American Association For Cancer Research ,Drug Administration ,Clinical Development Program ,International Staging System ,Exchange Commission ,Regeneron Pharmaceuticals Inc ,Cancer Research ,Annual Meeting ,Cancer Center ,York City ,Fast Track Designation ,Priority Review ,Linvoseltamab Phase ,Clinical Development ,Regeneron Genetics ,Looking Statements ,Product Candidates ,Medicines Agency ,